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Abstract 
The objective of this study is to clarify to what extent he accumulation of liposomes from the blood into the tumor and bone marrow 
can be controlled by liposome size and membrane fluidity. Liposomes with different diameters (50-400 nm) and different membrane 
fluidity were prepared from hydrogenated egg phosphatidylcholine (HEPC) or egg phosphatidylcholine (EPC), cholesterol (Ch) and 
dicetylphosphate in various molar ratios. These liposomes were injected intravenously into rats bearing Yoshida sarcoma, and the ratios of 
the accumulation of liposomes in the tumor to those in the bone marrow, liver and spleen were compared. The tumor-to-bone marrow 
accumulation ratio increased with the decrease in liposome size from 400 to 50 rim. This ratio was greater than those for the liver and 
spleen at all sizes. Although tumor-to-liver accumulation ratios of 50- and 100-rim HEPC-containing liposomes were higher than those of 
EPC-containing liposomes, no obvious difference in tumor-to-bone marrow or tumor-to-spleen accumulation ratios was found between 
these liposomes. Tumor-to-bone marrow accumulation ratio of HEPC-containing liposomes increased remarkably with the decrease in Ch 
content from 40 to 30 or 20 tool% compared with ratios for the liver and spleen. Interestingly, the tumor uptake clearance of liposomes of 
the same size was constant regardless of their membrane fluidity. These findings show that the increases in these accumulation ratios are 
due to their decreased uptake clearance by the bone marrow. Furthermore, the uptake of 50-nm HEPC-containing liposomes by the bone 
marrow was specifically inhibited by preinjection of other liposomes, but not when they were exposed in advance to in vivo components. 
These observations suggest the involvement of in vivo component(s) in the uptake of these liposomes by the bone marrow. We conclude 
that small HEPC-liposomes with low Ch content show their significantly decreased uptake by the bone marrow due to their decreased 
recognition by this tissue. 
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1. Introduction 
The change in the biodisposition of an antitumor agent 
by encapsulation i  l iposomes has been expected to in- 
crease its accumulation i  the tumor or reduce its toxicity, 
thereby enhancing its therapeutic usefulness. The encapsu- 
lation of an antitumor drug in liposomes has been reported 
to effectively reduce systemic toxicity [1] and toxicity in 
organs such as the heart [2] and kidney [3] due to the slow 
Abbreviations: HEPC, hydrogenated gg phosphatidylcholine; EPC, 
egg phosphatidylcholine; Ch, cholesterol; DCP, dicetylphosphate; RES, 
reticuloendothelial system; P, steady-state fluorescence polarization; 
AUC, area under the curve. 
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release of the drug from liposomes in blood circulation or 
reduced drug accumulation in these organs. However, 
pharmacokinetic alteration by liposomes includes the pos- 
sibility of an increase in toxicity in some organs or genera- 
tion of new toxicity [4]. Liposomes tend to accumulate 
more in tissues belonging to the reticuloendothelial system 
(RES) such as liver, spleen and bone marrow, compared 
with others [5]. Thus, toxicity in the RES may be increased 
or generated by the administration of liposomes containing 
an antitumor agent. 
In particular, myelosuppression is the most important 
toxicity in the RES, since it serves to greatly limit the dose 
of many antitumor agents. Indeed, for doxorubicin [6] and 
cisplatin analog [3] encapsulated in liposomes, leukopenia 
is likely to be the dose-limiting toxicity in humans. We 
have also observed that the considerable decrease in num- 
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ber of leukocytes in the blood is induced by daunorubicin 
which is encapsulated in liposomes composed of hydro- 
genated egg phosphatidylcholine, cholesterol and 
dicetylphosphate in a molar ratio of 5:4:1, although this 
liposome preparation showed superior antitumor activity to 
free daunorubicin [7]. To minimize the myelosuppression, 
it would be necessary to formulate liposomes o that their 
accumulation in the tumor tissue may be as high as 
possible relatively to that in the bone marrow, a major 
hematopoietic and lymphopoietic tissue. Such liposomes 
will be very useful drug-carriers for cancer chemotherapy. 
The uptake of liposomes by RES is well known to be 
influenced by various their physicochemical factors such 
as their size [8], surface charge [9], surface hydrophilicity 
[10] and membrane fluidity [11]. These factors are thought 
to affect the interaction of opsonins with the liposomal 
surface. Several investigators [12-16] have shown that 
serum contains specific opsonins for macrophages in the 
liver, spleen and bone marrow. Thus, the mechanisms 
underlying the uptake of liposomes by these organs may 
not always be common. Recently, we [17] and others 
[14,18] reported that the circulation time of liposomes in 
the blood and their size was important in determining their 
accumulation in tumor tissue. Furthermore, we demon- 
strated that the accumulation of liposomes from the blood 
into the tumor was dependent only on their size, and not 
on their circulation time in the blood [17]. These findings 
suggest that different mechanisms are involved in the 
accumulation of liposomes from the blood into the tumor 
and bone marrow, and therefore, the accumulation of 
liposomes into these tissues may be controlled by utilizing 
these differences. 
In this study, we investigated the effects of the physico- 
chemical characteristics of liposomes on their accumula- 
tion in the tumor and bone marrow using tumor-bearing 
rats. We focused here on the size and membrane fluidity of 
liposomes as their physicochemical f ctors. 
2. Materials and methods 
2.1. Materials 
Hydrogenated gg phosphatidylcholine (HEPC) and egg 
phosphatidylcholine (EPC) were kindly supplied by Nip- 
pon Fine Chemical (Osaka, Japan) and Nippon Oil &Fats 
(Tokyo, Japan), respectively. Cholesterol (Ch) was ob- 
tained from Wako Pure Chemical Industries (Osaka, Japan). 
Dicetylphosphate (DCP) was obtained from Nacalai Tesque 
(Kyoto, Japan). [3H]Cbolesteryl hexadecyl ether was pur- 
chased from NEN (Boston, MA, USA). Other chemicals 
used were of reagent grade. 
2.2. Preparation of  liposomes 
All liposome preparations were labeled with a trace of 
[3H]cholesteryl hexadecyl ether (1 /zCi/40 /zmol of total 
lipids) as a lipid phase marker. This lipid label has been 
demonstrated to be non-metabolizable [19] and non-ex- 
changeable [19,20]. The radiolabeled liposomes composed 
of HEPC or EPC, Ch and DCP in a molar ratio of 5:4:1, 
6:3:1 or 7:2:1 were prepared as reported previously [20] 
with a minor modification. In brief, these lipids were 
dissolved in chloroform with a trace of [3H]cholesteryl 
hexadecyl ether and the solvent was evaporated in vacuo. 
The obtained lipid films (200 /~mol as total lipids) were 
hydrated in 5 ml of phosphate-buffered saline (Na2HP Q 
1.15 g, KH2P Q 0.2 g, NaC1 8 g, KC1 0.2 g/ l ;  pH 7.4; 
PBS). Some of these liposome suspensions were extruded 
through a polycarbonate membrane filter (Nuclepore, 
Pleasanton, CA, USA) with a pore size of 0.4, 0.2 or 0.1 
/xm. The others were sonicated into small unilamellar 
vesicles using a probe-type sonicator (UR-200P, Tomy, 
Tokyo, Japan) until they became transparent for 90 rain on 
ice, and then centrifuged at 100000 ×g for 60 rain to 
remove large particles and make their size homogeneous. 
The final concentration f total lipids was approx. 40 raM. 
The liposome size was determined by the dynamic light 
scattering with a submicron particle analyzer (Nicomp 
model 370, Particle Sizing Systems, Santa Barbara, CA, 
USA). 
2.3. Steady-state fluorescence polarization (P) of  liposome 
membranes 
The degree of fluorescence polarization of diphenylhex- 
atriene in liposomes at 37°C was used as a parameter to 
determine membrane fluidity, and determined according to 
the method of Shinitzky and Barenholz [22] with slight 
modifications. 12 ml of 0.5 mM liposome suspensions 
were incubated with 0.4 ~1 of 6 mM diphenylhexatriene i  
N,N-dimethylformamide at 37°C for 75 min. The fluores- 
cence intensity of diphenylhexatriene was then measured 
by excitation and emission wavelengths of 360 and 425 
nm, respectively, at 37°C, and the degree of fluorescence 
polarization (P)  was calculated by the following equation. 
e = (I,, v - G.  Ivh) / ( I , ,  ~ + G' l , .h)  
G = lh,,/lhh 
where I,, v and Ivh are the vertical and horizontal compo- 
nents of fluorescence intensity of diphenylhexatriene ex-
cited by vertically polarized light, respectively. G is the 
correction factor, and Ihv and lhh are the vertical and 
horizontal components of fluorescence intensity obtained 
using horizontally polarized light, respectively. 
2.4. Inoculation of  tumor cells into rats 
Yoshida sarcoma cells (5. l0 6 cells) were subcuta- 
neously implanted into the right backs of male Donryu rats 
(5 weeks old, SLC, Shizuoka, Japan) as described previ- 
ously [17]. The implantation site was located between the 
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axilla and thoractic spine. Rats were used for experiments 
4 or 5 days after implantation. 
2.5. Biodistribution ~)[ Iiposomes 
3H-Labeled liposomes were intravenously injected via 
the tail vein at a dose of 100 /zmol lipid/kg. After 
specified periods, the animals were anesthetized by diethyl 
ether and blood samples were then taken from the abdomi- 
nal vein. Immediately, the abdominal vein and artery were 
cut and the animals were sacrificed by bleeding. Tumor, 
liver and spleen were then removed and weighed. A 
femoral bone was also removed and vertically divided into 
two pieces. Bone marrow was taken from these pieces and 
weighed. After decolorization with 35% H202 and disso- 
lution with 2 M KOH in isopropyl alcohol [21], the 
radioactivity in each sample was measured with an Aloka 
LSC-700 liquid scintillation counter. The weights of blood 
and bone marrow were assumed to be 6.5 and 3% of the 
body weight, respectively [23]. The area under the blood 
concentration-time curve (AUC) was calculated by the 
trapezoidal rule [24]. The tumor-to-tissue accumulation 
ratio and the uptake clearance by each tissue were calcu- 
lated by dividing the amount (% dose/g) of liposomes 
accumulated in the tumor by that obtained for each tissue 
and by the corresponding AUC, respectively. 
In another set of experiments, 3H-labeled liposomes 
(200 /xmol lipid/kg) were injected intravenously into rats, 
and recovered from the blood 15 min after injection. 
Immediately, these blood samples were centrifuged (3000 
rpm, 4°C, 15 rain) to obtain the plasma containing 3H- 
labeled liposomes. The obtained plasma or 3H-labeled 
liposomes without exposure to in vivo components were 
injected at a dose of 50 /xmol l ipid/kg into another group 
of rats preinjected 1 or 24 h previously with unlabeled 
liposomes (100 p, mol lipid/kg). 1 h after the injection, 
blood samples, bone marrow and other tissues were ob- 
tained as described above. In these experiments, since 
there was plenty of the radioactivity in the blood 1 h after 
injection, we corrected the blood content in each tissue. 
Correction factors for the blood content in tissues were 
determined using the [51Cr ]RBC method [14] (Kiwada, H., 
unpublished ata). 
2.6. Statistics 
Following the F-test, statistical analysis was performed 
using Student's t-test, Aspin-Welch test or Cochran test. 
Differences were considered significant at P < 0.05. 
3. Results 
3. l. Effects of liposome size on distribution of HEPC-con- 
raining liposomes in tumor and bone marrow 
Fig. 1 shows the effects of liposome size on tumor-to- 
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Fig. 1. Effects of l iposome size on tumor-to-tissue accumulation ratios of 
HEPC/Ch/DCP (5:4:l)-l iposomes 24 h after intravenous administration 
in Yoshida sarcoma-bearing rats. 3H-Labeled liposomes were injected 
intravenously into tumor-bearing rats at a dose of 100 /xmol l ip id/kg.  
Tumors, bone marrow (O),  livers (A) and spleens (D)  were removed 
and weighed 24 h after intravenous injection. Values are the mean + S.E. 
of three or four rats. Significantly different from tumor-to-bone marrow 
ratio: * P < 0.05; * ~ P < 0.01. 
liposomes composed of HEPC, Ch and DCP in a molar 
ratio of 5:4:1 (HEPC/Ch/DCP (5:4:l)-liposomes) 24 h 
after intravenous injection into Yoshida sarcoma-beating 
rats. The ratio for the bone marrow was greater than those 
for the liver and spleen at all liposome sizes and decreased 
with the increase in the size. Similar size-dependency was 
observed in the ratio for the spleen. The ratio for the liver 
was the highest with liposomes of about 100 nm in diame- 
ter. 
3.2. Eff'ects of HEPC and Ch on membrane fluidio' of 
liposomes 
The membrane fluidity of liposomes is known to be 
regulated by the inclusion of a saturated phospholipid with 
high phase-transition temperature (such as HEPC) [25] and 
Ch [9,12] in the bilayers. Fig. 2 shows effects of Ch 
content on the membrane fluidity of HEPC- and EPC-con- 
taining liposome. The membrane fluidity was expressed as 
P-value. This parameter decreases with the increase in 
membrane fluidity. When the Ch content was decreased 
from 40 to 30 or 20 mol%, the P-value of HEPC-contain- 
ing liposomes was virtually unchanged, while that of 
EPC-containing liposomes decreased. 
3.3. Effects of membrane fluidiO' of liposomes on their 
distribution in tumor and bone marrow 
Fig. 3 shows the effects of membrane fluidity on tumor 
uptake clearance of liposomes with diameters of 50 and 
100 nm. The clearance of liposomes of the same size was 
constant regardless of membrane fluidity or lipid composi- 
tion. 
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Fig. 2. Effects of HEPC and Ch on membrane fluidity of liposomes. The 
P-value, an order parameter of membrane fluidity, was measured at 37°C 
as described in Section 2, using 50- or 100-nm liposomes composed of 
HEPC or EPC, Ch and DCP in a molar ratio of 5:4:1, 6:3:1 or 7:2:1. Only 
the size of HEPC/Ch/DCP (7:2:l)- l iposomes was 100 nm, since 50-nm 
ones could not be prepared in this molar ratio. The size of l iposomes with 
other lipid compositions was 50 nm. Closed and open symbols represent 
HEPC- and EPC-containing liposomes, respectively. Values are the 
means + S.E. of two or three experiments. 
Fig. 4A and B show the tumor-to-bone marrow, -liver 
and -spleen accumulation ratios of 50- and 100-nm lipo- 
somes with various membrane fluidity, respectively. These 
ratios, especially the tumor-to-bone marrow accumulation 
ratio, were greater at low Ch content (< 30 mol%) for 
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Fig. 3. Tumor uptake clearance of l iposomes with various membrane 
fluidity. 3H-Labeled liposomes with a diameter of about 50 nm (0)  or 
100 nm(  • ) were injected intravenously into tumor-bearing rats at a dose 
of 100 /zmol l ip id/kg.  At appropriate intervals up to 24 h after intra- 
venous injection, blood samples were taken via the abdominal vein and 
then tumors were removed and weighed. The tumor uptake clearance of 
l iposomes was calculated by dividing the total amount of liposomes 
accumulated in the tumor until 24 h by the corresponding AUC. Values 
of tumor uptake clearance are the means + S.E. of three or four rats. 
P-values are the means-t-S.E, of two or three experiments. 
P-value 
Fig. 4. Effects of membrane fluidity on tumor-to-tissue accumulation 
ratios of liposomes with diameters of about 50 nm (A) and 100 nm (B) 24 
h after intravenous injection into Yoshida sarcoma-bearing rats. The 
details of this experiment and symbols are the same as in Fig. 1. Values 
are the means-I-S.E, of three or four rats. Significantly different from 
HEPC/Ch/DCP (5:4:l)-l iposomes: * P < 0.05; * * P < 0.01. 
was almost the same in the Ch content range (20-40 
mol%). However, these ratios were not significantly differ- 
ent in EPC-containing liposomes with different Ch content, 
which showed obviously different fluidity. Although 
HEPC-containing liposomes howed higher tumor-to-liver 
accumulation ratios than EPC-containing liposomes, there 
was no obvious difference in tumor-to-bone marrow or 
tumor-to-spleen accumulation ratios between both types of 
liposomes. 
3.4. Effects of  in vivo components on distribution of lipo- 
somes in bone marrow 
To clarify the involvement of in vivo component(s) in
the uptake of liposomes by the bone marrow, we investi- 
gated whether the accumulation of 3H-labeled liposomes in 
the bone marrow was inhibited by the preinjection of 
unlabeled liposomes and whether that of 3H-labeled lipo- 
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Fig. 5. Effects of in vivo components on accumulation of 50-nm 
HEPC/Ch/DCP (5:4:l)-liposomes in bone marrow. Column A (control, 
no preinjection): 3H-labeled liposomes (100 /xmol lipid/kg) were in- 
jected intravenously into rats. Columns B and C: 3H-labeled liposomes 
(50 /xmol lipid/kg) were injected intravenously into rats preinjected 24 
and 1 h previously with unlabeled liposomes (100 /.tmol lipid/kg), 
respectively. Column D: 3H-labeled liposomes associated with in vivo 
components were injected intravenously into rats preinjected with unla- 
beled liposomes under the same condition as in the column C. Liposomes 
associated with in vivo components were obtained as follows: 3H-labeled 
liposomes (200 tzmol lipid/kg) were injected intravenously into rats and 
recovered from the blood 15 min after injection; the blood samples were 
immediately centrifuged (3000 rpm, 4°C, 15 min) to obtain the plasma 
containing 3H-labeled liposomes. Bone marrow was removed 1 h after 
injection of ~H-labeled liposomes. Values are the means+S.E, of four 
rats. Significant difference: * P < 0.05; * * P < 0.01. 
somes associated with in vivo components was affected by 
the preinjection of unlabeled iiposomes. In these experi- 
ments, 50-nm HEPC/Ch/DCP (5:4:l)-liposomes were 
used, and liposomes associated with in vivo components 
were obtained by the exposure to in vivo components for 
15 min after intravenous injection into rats. The results of 
these experiments are shown in Fig. 5. The preinjection of 
unlabeled liposomes 24 h prior to administration of labeled 
liposomes did not inhibit their accumulation i the bone 
marrow 1 h after their intravenous injection (column B). 
However, the preinjection of unlabeled liposomes 1 h prior 
to administration of labeled liposomes ignificantly inhib- 
ited their accumulation in the bone marrow l h after 
intravenous injection (column C). When labeled liposomes 
exposed to in vivo components for 15 min were intra- 
venously injected 1 h after the preinjection of unlabeled 
liposomes, no inhibitory effect of preinjection of unlabeled 
liposomes was observed (column D). 
4. Discussion 
We demonstrated previously that the uptake clearance 
of liposomes by tumors depended primarily on their size 
and that of liposomes with a diameter of 100 nm was 
maximum [17]. The observation that the tumor uptake 
clearance of liposomes of the same size was constant 
regardless of their membrane fluidity or lipid composition 
(Fig. 3) is consistent with this finding. The tumor-to-tissue 
accumulation ratio is equal to the tumor-to-tissue uptake 
clearance ratio, since the uptake clearance is calculated by 
dividing the accumulation amount by AUC. Thus, the 
increased ratios for the bone marrow or spleen of 50-nm 
HEPC-containing liposomes (Fig. 1) are due to decreased 
uptake clearance by these tissues. Also, as the tumor 
uptake clearance of liposomes of the same size was con- 
stant (Fig. 3), the increased tumor-to-tissue accumulation 
ratios as shown in Fig. 4 are due to decreased uptake 
clearance of liposomes by the liver, spleen and bone 
marrow. On the other hand, the decreased tumor-to-liver 
accumulation ratio of 50-nm HEPC-containing liposomes 
(Fig. 1) is due to decreased their uptake clearance by the 
tumor, because the uptake clearance of HEPC-containing 
liposomes by the liver decreased with the decrease in 
liposome size (data not shown). Therefore, it is considered 
that, at smaller size and lower Ch content, the uptake 
clearance of HEPC-containing liposomes by the bone mar- 
row was dramatically reduced without changes in their 
tumor uptake clearance. Such decreased uptake clearance 
of liposomes by the bone marrow could be attributed to the 
difference between the mechanisms by which they accu- 
mulate in the tumor and bone marrow. 
The marked change in tumor-to-bone marrow accumu- 
lation ratio of Ch-poor HEPC-containing liposomes ug- 
gests some in vivo component(s) involved in the uptake of 
liposomes by the bone marrow. The results shown in Fig. 
5 strongly support his possibility. These results also show 
that the in vivo component(s) is (are) subject o temporary 
depletion at an early stage after intravenous injection of 
liposomes. 
Although the mechanism of the uptake of liposomes by 
the bone marrow is unknown, several in vitro studies have 
shown Ch-dependent uptake of multilamellar liposomes by 
macrophages in the bone marrow. Moghimi and Patel [16] 
suggested the involvement of serum components in the 
uptake of Ch-rich EPC-containing liposomes by reticulo- 
endothelial cells in the bone marrow. The in vivo findings 
of the present study using small liposomes ( Figs. 4 and 5) 
are consistent with this finding, and thus the uptake of 
these liposomes by the bone marrow may be mediated by 
similar serum components. This possibility is supported by 
a microscopic observation [26] that about 100-nm lipo- 
somes containing monosialoganglioside localized exclu- 
sively in the resident macrophages in the bone marrow. 
Allen et al. [27] presented a contrary report that the bone 
marrow macrophages showed low affinity for Ch-rich 
EPC-containing liposomes compared with those poor in 
Ch. However, this may not apply to our in vivo results, 
since it was obtained in the absence of serum. 
Recently, a Ch-specific factor which associates with Ch 
molecules on the surface of PC-containing multilamellar 
liposomes to activate the alternative complement pathway 
was found in rat plasma [28]. Moghimi and Patel [16] 
suggested the possibility of the involvement of serum 
34 A. Naga,msu et al. / Biochimica et Biophysica Acta 1278 (1996) 29-34 
components other than complement in the uptake of Ch- 
containing liposomes by bone marrow macrophages. Un- 
fortunately, we have no evidence to clarify the nature of 
the factor(s) adsorbed on the surface of small liposomes. 
The decreased bone marrow uptake in Ch-poor HEPC-con- 
taining liposomes of small size may be due to the de- 
creased interaction of the in vivo component(s) with the 
liposome surface. 
The size of liposomes is a factor determining the magni- 
tude of their interaction with plasma proteins such as 
opsonins [29]. The small size tends to decrease the interac- 
tion of plasma proteins with liposomes. This may explain 
the size-dependent decrease in the uptake clearance of 
liposomes by the bone marrow. 
The composition of both HEPC and Ch appears to be 
responsible for the decreased bone marrow uptake in Ch- 
poor HEPC-containing liposomes, because an incomplete 
correlation was observed between the membrane fluidity 
or Ch content of liposomes and the tumor-to-bone marrow 
accumulation ratio (Fig. 4). The decrease in the fluidity of 
liposome membranes has been shown to decrease the 
interaction of plasma proteins with the membranes [9,11 ], 
and thus HEPC-containing liposomes with less membrane 
fluidity (Fig. 3) may show less interaction with proteins. 
However, Ch-poor HEPC-containing liposomes showed 
remarkably high tumor-to-bone marrow ratios, although 
their membrane fluidity was almost comparable to that of 
Ch-rich liposomes ( Figs. 3 and 4). This suggests that the 
decreased uptake clearance of HEPC-containing liposomes 
by the bone marrow may be dependent on Ch content 
rather than membrane fluidity. The decreased Ch content 
may directly reduce Ch-dependent interaction of in vivo 
component(s) with the bilayers of HEPC-containing lipo- 
somes, and this may be assisted by the decreased mem- 
brane fluidity. 
There are discrepancies between the dependency of the 
accumulation ratios for the bone marrow, liver and spleen 
on liposome size and fluidity ( Figs. 1 and 4). This 
suggests different mechanisms underlying the accumula- 
tion of liposomes in these RES tissues. Several in vitro 
studies also suggest that liposomes are taken up by 
macrophages in these tissues through different opsonins 
[ 12,13,16,27]. Therefore, the accumulation of liposomes in 
the tumor and liver or spleen, as well as bone marrow, 
may be controlled by utilizing different mechanisms of the 
uptake of liposomes by these tissues. The answer to the 
title of this report is 'yes'. 
The control of the distribution of liposomes between the 
tumor and bone marrow is more significant than the 
control of their distribution between the tumor and liver or 
spleen, because their accumulation in the bone marrow 
will determine the magnitude of myelosuppression i duced 
by liposomal antitumor agents. Liposomes which allow 
controlled accumulation in the tumor, bone marrow and 
other organs may be utilized to lower the bone marrow 
toxicity of the liposome-encapsulated antitumor agent 
without reduction of antitumor activity. 
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